|Table of Contents|

Value of 18F-FDG PET/CT combined with inflammatory factors in peripheral blood in evaluating the efficacy of immunotherapy for advanced NSCLC

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 17
Page:
3209-3215
Research Field:
Publishing date:

Info

Title:
Value of 18F-FDG PET/CT combined with inflammatory factors in peripheral blood in evaluating the efficacy of immunotherapy for advanced NSCLC
Author(s):
XIE Fuxia; LI Mengdan; WANG Xiaohui; JING Xingguo
Department of Nuclear Medicine，The First Affiliated Hospital of Chongqing Medical University，Chongqing 400016，China.
Keywords:
non-small cell lung cancer(NSCLC); immune checkpoint inhibitors(ICIs); 18F-FDG PET/CT; derived neutrophil to lymphocyte ratio(dNLR)
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.17.012
Abstract:
Objective：To evaluate the prognostic value of quantitative parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography(18F-FDG PET/CT) combined with inflammatory factors in peripheral blood in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors(ICIs).Methods：In this retrospective double-center research，62 patients with advanced non-small cell lung cancer were collected.All patients received at least 4 courses of immunotherapy from November 2018 to October 2021.Patients were divided into the disease control group(n=42) and the disease progression group(n=20) based on the RECIST 1.1 criteria.The differences of clinical，hematological and 18F-FDG PET/CT parameters between the two groups were analysed.The risk factors influencing disease progression were tested by multivariate Logistic regression.The differences in cumulative survival rates was expressed by Kaplan-Meier survival curves.A multivariate prediction models for progression-free survival(PFS) and overall survival(OS) was established by Cox model.Results：Compared with the disease progression group,MTV,tMTV and dNLR were significantly decreased in the disease control group(P＜0.05).In multivariate Logistic regression analysis,dNLR>3 was an independent predictor factor of disease progression(P＜0.05).The median follow-up time was 19.0 months and 47 patients survived(75.8%,47/62).Cox multivariate regression analysis showed that dNLR>3 and tMTV>68.5 cm3 were independent factors to predict PFS.Kaplan-Meier survival curve showed that,the PFS and OS of patients in poor prognosis group(dNLR>3 and tMTV>68.5 cm3) were significantly lower than that in intermediate prognosis group(dNLR>3 or tMTV>68.5 cm3) and good prognosis group(dNLR≤3 and tMTV≤68.5 cm3)(P＜0.01).Conclusion：tMTV value of 18F-FDG PET/CT combined with dNLR has certain application value in predicting the prognosis of patients with advanced non-small cell lung cancer receiving immunotherapy.

References:

[1]LI CL,SONG Y.Combination strategies of immunotherapy in non-small cell lung cancer:facts and challenges［J］.Chin Med J(Engl),2021,134(16):1908-1919.
[2]CHENG Y,LI H,ZHANG L,et al.Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer［J］.Chinese Medical Journal,2021,134(15):1780-1788.
[3]HUMBERT O,CADOUR N,PAQUET M,et al.(18)FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy:frequency and clinical significance of atypical evolutive patterns［J］.Eur J Nucl Med Mol Imaging,2020,47(5):1158-1167.
[4]LOPCI E,TOSCHI L,GRIZZI F,et al.Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer(NSCLC) who are candidates for upfront surgery［J］.Eur J Nucl Med Mol Imaging,2016,43(11):1954-1961.
[5]WANG Y,ZHAO N,WU Z,et al.New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer［J］.European Journal of Nuclear Medicine and Molecular Imaging,2020,47(5):1127-1136.
[6]CHARDIN D,PAQUET M,SCHIAPPA R,et al.Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors:a prospective study［J］.J Immunother Cancer,2020,8(2):e000645.
[7]刘建清,骆华春,沈志勇,等.PLR和NLR与Ⅲ期非小细胞肺癌临床特征及同步放化疗联合免疫治疗疗效及预后的相关性［J］.实用癌症杂志,2022,37(05):763-768. LIU JQ，LUO HQ，SHEN ZY，et al.Relationship of peripheral blood neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with curative effect and prognosis of patients with Ⅲ stage non-small cell Lung cancer received concurrent chemoradiotherapy plus immunotherapy ［J］.The Practical Journal of Cancer，2022,37(05):763-768.
[8]MUNN LL.Cancer and inflammation［J］.Wiley Interdiscip Rev Syst Biol Med,2017,9(2):10.
[9]MANTOVANI A,ALLAVENA P,SICA A,et al.Cancer-related inflammation［J］.Nature,2008,454(7203):436-444.
[10]TAKADA K,TAKAMORI S,YONESHIMA Y,et al.Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy［J］.Lung Cancer,2020,145:18-26.
[11]ALESSI JV,RICCIUTI B,ALDEN SL,et al.Low peripheral blood derived neutrophil-to-lymphocyte ratio(dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer［J］.Journal for ImmunoTherapy of Cancer,2021,9(11):e3536.
[12]GOLDSTRAW P,CHANSKY K,CROWLEY J,et al.The IASLC lung cancer staging project:Proposals for revision of the TNM stage groupings in the forthcoming(Eighth) edition of the TNM classification for lung cancer［J］.J Thorac Oncol,2016,11(1):39-51.
[13]CASTELLO A,ROSSI S,TOSCHI L,et al.Comparison of metabolic and morphological response criteria for early prediction of response and survival in NSCLC patients treated with anti-PD-1/PD-L1［J］.Front Oncol,2020,10:1090.
[14]FERRUCCI PF,ASCIERTO PA,PIGOZZO J,et al.Baseline neutrophils and derived neutrophil-to-lymphocyte ratio:prognostic relevance in metastatic melanoma patients receiving ipilimumab［J］.Ann Oncol,2016,27(4):732-738.
[15]孙琦,文洽先,王庆华,等.PET/CT定量参数联合血液学指标对免疫检查点抑制剂联合化疗治疗晚期肺癌患者预后的预测价值［J］.天津医药,2022,50(04):399-403. SUN Q，WEN QX，WANG QH，et al.Predictive value of quantitative parameters of PET/CT combined with hematological indexes for prognosis of patients with advanced lung cancer treated by immune checkpoint inhibitor combined with chemotherapy［J］.Tianjin Medical Journal，2022,50(04):399-403.
[16]BAUCKNEHT M,GENOVA C,ROSSI G,et al.The role of the immune metabolic prognostic index in patients with non-small cell lung cancer(NSCLC) in radiological progression during treatment with nivolumab［J］.Cancers,2021,13(13):3117.
[17]GIBNEY GT,WEINER LM,ATKINS MB.Predictive biomarkers for checkpoint inhibitor-based immunotherapy［J］.Lancet Oncol,2016,17(12):e542-e551.
[18]ZHAO L,LIU J,SHI J,et al.Relationship between SP142 PD-L1 expression and 18F-FDG uptake in non-small-cell lung cancer［J］.Contrast Media & Molecular Imaging,2020,2020:1-11.
[19]KONERT T,VOGEL WV,PAEZ D,et al.Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries:preliminary results from the IAEA PERTAIN trial［J］.Eur J Nucl Med Mol Imaging,2019,46(11):2235-2243.
[20]SHARMA A,MOHAN A,BHALLA AS,et al.Role of various metabolic parameters derived from baseline 18F-FDG PET/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy［J］.Clin Nucl Med,2018,43(1):e8-e17.
[21]冯雪，孙莹莹，孙夕林.18F-FDG PET/CT代谢的可重复性研究进展 ［J］.现代肿瘤医学，2019，27（20）：3709-3712. FENG X,SUN YG,SUN XL.Advances in repeatability of 18F-FDG PET/CT metabolism［J］.Modern Oncology,2019，27（20）：3709-3712.
[22]ANGELO CASTELLO,SABRINA ROSSI,EMANUELA MAZZIOTTI,et al.Hyperprogressive disease in patients with non-small cell lung cancer treated with checkpoint inhibitors:The role of 18F-FDG PET/CT［J］.Journal of Nuclear Medicine,2020,61(6):821-826.
[23]SEBAN R,MEZQUITA L,BERENBAUM A,et al.Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors［J］.European Journal of Nuclear Medicine and Molecular Imaging,2020,47(5):1147-1157.
[24]IM HJ,PAK K,CHEON GJ,et al.Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer:a meta-analysis［J］.Eur J Nucl Med Mol Imaging,2015,42(2):241-251.
[25]FAGET J,PETERS S,QUANTIN X,et al.Neutrophils in the era of immune checkpoint blockade［J］.J Immunother Cancer,2021,9(7):e002242.
[26]KAZANDJIAN D,GONG Y,KEEGAN P,et al.Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer［J］.JAMA Oncol,2019,5(10):1481-1485.
[27]DALL OLIO FG,CALABRO D,CONCI N,et al.Baseline total metabolic tumour volume on 2-deoxy-2-［18F］fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab［J］.European Journal of Cancer,2021,150:99-107.
[28]SEBAN R,ASSIE J,GIROUX-LEPRIEUR E,et al.Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab［J］.Cancers,2020,12(8):2234.
[29]SEBAN R,ASSIe J,GIROUX-LEPRIEUR E,et al.Prognostic value of inflammatory response biomarkers using peripheral blood and ［18F］-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy［J］.Lung Cancer,2021,159:45-55.

Memo

Memo:
-
Last Update: 2023-07-31